

**Audited Financial Results for the quarter and financial year ended on 31/03/2015**

Part I		(Rs. In Lacs)				
Sr. No.	Particulars	Quarter ended			Year ended	
		31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014
		Audited	Unaudited	Audited	Audited	Audited
1	<b>Income from Operations</b>					
	(a) Net Sales/Income from Operations (Net of Excise Duty)	2224.55	2133.92	1993.20	8501.80	7620.00
	(b) Other Operating Income	11.26	4.31	0.30	19.24	2.45
	<b>Total Income from Operations (Net)</b>	<b>2235.81</b>	<b>2138.23</b>	<b>1993.50</b>	<b>8521.04</b>	<b>7622.45</b>
2	<b>Expenses</b>					
	(a) Cost of Materials Consumed	662.98	685.31	667.32	2657.02	2473.41
	(b) Purchases of Stock in Trade	0.25	0.00	0.00	1.40	0.61
	(c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	17.82	-39.39	62.68	-65.26	77.07
	(d) Employee benefits Expense	467.63	488.61	422.76	1899.32	1696.57
	(e) Depreciation and amortisation Expense	77.56	68.34	42.81	265.90	155.31
	(f) Other Expenses	684.69	584.40	564.93	2503.24	2223.11
	<b>Total Expenses</b>	<b>1910.93</b>	<b>1787.27</b>	<b>1760.50</b>	<b>7261.62</b>	<b>6626.08</b>
3	Profit from Operations before other income, finance cost and exceptional items (1-2)	<b>324.88</b>	<b>350.96</b>	<b>233.00</b>	<b>1259.42</b>	<b>996.37</b>
4	Other Income	158.19	18.28	71.51	207.24	161.16
5	Profit from Ordinary activities before finance costs and exceptional items (3+4)	<b>483.07</b>	<b>369.24</b>	<b>304.51</b>	<b>1466.66</b>	<b>1157.53</b>
6	Finance Cost	9.24	10.22	-2.77	35.65	126.50
7	Profit from ordinary activities after finance cost but before exceptional items (5-6)	<b>473.83</b>	<b>359.02</b>	<b>307.28</b>	<b>1431.01</b>	<b>1031.03</b>
8	Exceptional Items	2.82	0.00	0.95	2.98	1.85
9	Profit from Ordinary activities before tax (7+8)	<b>476.65</b>	<b>359.02</b>	<b>308.23</b>	<b>1433.99</b>	<b>1032.88</b>
10	Tax Expense					
	Current	209.50	123.00	77.25	512.50	289.93
	Deferred	43.35	-65.52	0.00	-43.42	-7.68
11	Net Profit from Ordinary activities after tax (9-10)	<b>223.80</b>	<b>301.54</b>	<b>230.98</b>	<b>964.91</b>	<b>750.63</b>
12	Extra ordinary items (Net of Tax Expense)	0.00	0.00	0.00	0.00	0.00
13	Net Profit for the period (11+12)	<b>223.80</b>	<b>301.54</b>	<b>230.98</b>	<b>964.91</b>	<b>750.63</b>
14	Share of Profit / (Loss of Associates)	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00
16	Net Profit after taxes, minority interest and share of profit of Associates (13+14-15)	<b>223.80</b>	<b>301.54</b>	<b>230.98</b>	<b>964.91</b>	<b>750.63</b>
17	Paid-up equity share capital (Face Value of Rs. 10/- each)	464.93	464.93	464.93	464.93	464.93
18	Reserve excluding Revaluation - Reserves as per Balance Sheet of previous accounting year	-	-	-	2878.94	2265.73
19 i	Earnings per share (EPS) (before extraordinary items) (of face value of Rs. 10/- each) (not annualised)					
	(a) Basic	4.81	6.49	4.97	20.75	16.15
	(b) Diluted	4.81	6.49	4.97	20.75	16.15
19 ii	Earnings per share (EPS) (after extraordinary items) (of face value of Rs. 10/- each) (not annualised)					
	(a) Basic	4.81	6.49	4.97	20.75	16.15
	(b) Diluted	4.81	6.49	4.97	20.75	16.15



PART II						
Sr. No.	Particulars	Quarter ended			Year ended	
		31/03/2015	31/12/2014	31/03/2014	31/03/2015	31/03/2014
		Audited	Unaudited	Audited	Audited	Audited
A.	Particulars of Shareholding					
1	Public shareholding					
	- Number of shares	2494513	2462736	2472690	2494513	2472690
	- Percentage of shareholding	53.65	52.97	53.18	53.65	53.18
2	Promoters and Promoter Group Shareholding					
	a) Pledged / Encumbered					
	- Number of shares	0	0	0	0	0
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0	0
	- Percentage of shares (as a % of the total share capital of the company)					
	b) Non - encumbered					
	- Number of shares	2154787	2186564	2176610	2154787	2176610
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	46.35	47.03	46.82	46.35	46.82
	<b>Particulars</b>	<b>31/03/2015</b>				
B	<b>INVESTOR COMPLAINTS</b>					
	Pending at the beginning of the quarter	Nil				
	Received during the quarter	2				
	Disposed of during the quarter	2				
	Remaining unresolved at the end of the quarter	Nil				

**Notes:**

- The figures of previous quarters / year have been reclassified / regrouped / rearranged wherever necessary.
- The above audited financial results for the financial year ended on 31st March, 2015, were taken on record by the audit committee and approved by board of directors of the Company at their respective meetings held on 21st May, 2015.
- The Board of Directors have recommended a dividend of Rs.6.30 (63%) per equity shares of Rs. 10/- each.
- The Company is dealing exclusively in pharmaceuticals business segment, hence segmentwise reporting is not applicable.
- Figures of the last quarters are the balancing figures between the audited figures in respect of full financial year and the published year to date figure upto the end of the third quarter (December 2014) of the financial year 2014-15.
- Persuant to applicability of Schedule II to the Company's Act 2013, with effect from 01/04/2014, the Company has reviewed and revised the estimated useful lives of Fixed Assets in accordance with the said provisions. On account of this change an amount of Rs. 8.15 Lacs representing WDV of those Fixed Assets whose useful life expired as on 1st April 2014 have been adjusted against the opening Profit & Loss appropriation account and has also resulted into an adjustment of Rs. 2.64 Lacs in deferred tax. Had there been no change, Depreciation charged for the year ended 31st March, 2015 would have been lower by Rs. 125.63 Lacs.
- National Pharmaceutical Pricing Authority (NPPA) had served a Show Cause Notice to the company alleging that a company's product was violating NPPA's standing order. However after a Personal Hearing and detailed submission, NPPA passed a written order stating that the Company's product did not violate the said standing order. Subsequently, NPPA reviewed its own order without having any power to review and issued Show Cause Notices and Demand Notice to the company. The company subsequently filed a writ petition against the demand of NPPA, at the Hon'ble High Court of Bombay. As the matter was reviewed by NPPA without the power to do, as per Drugs (Pricing Control) Order, 1995, the demand order and Show Cause Notices of NPPA were quashed by the Hon'ble High Court of Bombay. Hence the matter was settled in favour of the company. The NPPA after over a year filed a Special Leave Petition (SLP) at Hon'ble Supreme Court, where the matter is pending. DPCO, 1995, explicitly debars NPPA to review its own order, the very reason cited by Hon'ble High Court of Bombay, while quashing Show Cause Notices and demand notice in their Judgement dated 08th August, 2013 and 26th September, 2013. The company has been legally advised, that based on the facts and merits of the case, the demand raised by NPPA is not likely to crystallise.




**STATEMENT OF ASSETS AND LIABILITIES AS AT 31.03.2015**

Particulars		(Rs. In lac)	
		31.03.2015	31.03.2014
<b>A. EQUITY &amp; LIABILITIES</b>			
<b>1 Share Holders Fund</b>			
a) Share Capital	464.93		464.93
b) Reserves & Surplus	2878.94		2265.73
c) Money received against Share Warrants	0.00		0.00
<b>Sub-total Shareholders' fund</b>		3343.87	2730.66
<b>2 Share application money pending allotment</b>		0.00	0.00
<b>3 Minority Interest</b>		0.00	0.00
<b>4 Non Current Liabilities</b>			
a) Long Term Borrowings	0.63		3.61
b) Defferred Tax Liability (Net)	76.26		119.68
c) Other Long Term Liabilities	269.29		257.62
d) Long Term Provisions	0.00		0.00
<b>Sub total Non-current liabilities</b>		346.18	380.91
<b>5 Current Liabilities</b>			
a) Short Term Borrowings	660.80		198.33
b) Trade Payables	382.33		410.20
c) Other Current Liabilities	479.89		394.51
d) Short Term Provisions	872.20		286.07
<b>Sub total Current liabilities</b>		2395.22	1289.11
<b>TOTAL - EQUITY AND LIABILITIES</b>		<b>6085.27</b>	<b>4400.68</b>
<b>B. ASSETS</b>			
<b>1 Non Current Assets</b>			
a) Fixed Assets	1160.45		1357.05
b) Goodwill on Consolidation	0.00		0.00
c) Non Current Investments	31.21		31.21
d) Defferred Tax Assets (Net)	0.00		0.00
e) Long Term Loans & Advances	0.00		0.00
f) Other Non Current assets	33.26		33.26
<b>Sub total Non-current assets</b>		1224.92	1421.52
<b>2 Current Assets</b>			
a) Current Investments	0.00		0.00
b) Inventories	758.04		650.34
c) Trade Receivables	737.52		548.31
d) Cash & Cash Equivalents	2750.78		1674.80
e) Short Term Loans & Advances	48.99		30.27
f) Other Current Assests	565.02		75.44
<b>Sub total - Current assets</b>		4860.35	2979.16
<b>TOTAL ASSETS</b>		<b>6085.27</b>	<b>4400.68</b>

 Place : Mumbai  
 Date : 21/05/2015

 By order of the Board  
 For Jenburkt Pharmaceuticals Ltd.



(Ashish U. Bhuta)

Chairman and Managing Director.

